Novartis Consumer Health Inc competitors

Jean-Jacques Bienaime is a Board Member at Biotechnology Innovation Organization - BIO, Director at INCYTE CORP, and Chairman/CEO at BioMarin Pharmaceutical Inc and is based in Novato, California. He has experience at Rhône Poulenc Rorer and has worked as President/CEO at GENENCOR INTERNATIONAL INC, Board Member at NeurogesX Inc, and Marketing Director at Genentech. Jean attended ESCP Europe, Ecole Superieure de Commerce de Paris between 1974 and 1976, and University of Pennsylvania.

Dr. Singh was elected President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and appointed to our board of directors in August 2019. Previously Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined PerkinElmer as the President of our Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 and Executive Vice President in March 2018. Prior to joining PerkinElmer, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region. Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals. Dr. Singh has more than twenty-five years of leadership experience with global innovators in healthcare technology. He has spent the most recent six years developing unique insights into both our business and our opportunities for continued growth. Dr. Singh brings to our board a detailed understanding of the core technologies that we utilize and the operational strategies available to us as we continue to focus on innovating for a healthier world.

Founder of Sirius XM radio and United Therapeutics. Progressive technologist and green energy advocate. Helicopter, fixed wing pilot.

Andy Eckert is a proven leader across multiple sectors of healthcare, including Medical Devices, HCIT and Services. Most recently, Andy was the CEO of Acelity, a leading provider of innovative wound care solutions and products. Under Andy’s leadership, Acelity increased its investment in R&D and new product commercialization, resulting in an impressive acceleration of top-line growth and the sale to 3M in 2019 for $6.7B. Prior to Acelity, Andy served as CEO of TriZetto, the leading enterprise software solution for commercial payors, where he sharpened the company’s strategic focus and guided TriZetto to a successful sale to Cognizant in 2014 for $2.7B. In addition, Andy has recently served as CEO of Valence Health, an emerging leader in value-based healthcare, and Chairman and CEO of CRC Health Group, a leading behavioral health treatment provider now part of Acadia. Earlier in his career, Andy was CEO of Eclipsys Corporation and CEO of SumTotal. He began his career at ADAC Laboratories, including four years as Chairman and CEO until its sale to Philips Medical Systems in 2000. Andy has also served on a number of corporate boards and is currently the Chairman of Varian Medical Systems (NYSE: VAR and a Director at Becton, Dickinson and Company (NYSE: BDX). He has a Bachelor of Science in Industrial Engineering and a Master of Business Administration, both from Stanford University.

Alexander Hardy is the CEO of Genentech. Hardy, who joined Genentech in 2005, has served as CEO since March 1, 2019. He previously served as head of global product Strategy for Roche Pharmaceuticals. Previously, he headed up Asia Pacific for Roche's pharma outfit.

Geoff Martha is firmly establishing Medtronic as the undisputed global leader in healthcare technology. As chairman & CEO, Geoff leads the $30 billion company and its 90,000 employees in pursuit of fulfilling the Medtronic Mission to use technology to improve human welfare. He is recognized as a driven and innovative executive - ranking in Modern Healthcare’s 100 Most Influential People in Healthcare in 2020 and listed as the #1 CEO in healthcare technology by the Healthcare Technology Report in 2021.Geoff became CEO in April 2020. Under his leadership, Medtronic is putting the ‘tech’ in MedTech, leveraging the latest advances in cutting edge technology to transform healthcare. Fortune Magazine named Medtronic among the top 15 companies for its 2020 “Change the World” list, recognizing its swift efforts during the pandemic, and listed the company on its 2021 list of Most Admired Companies.Geoff joined Medtronic in 2011, and notably led the acquisition and integration of Covidien, the largest acquisition in the medical technology industry. Before joining Medtronic, Geoff spent 19 years at GE Healthcare and GE Capital.Geoff is a member of the Business Roundtable, and the World Economic Forum’s International Business Council. He also co-chairs the Taskforce on Health and Life Sciences for B20, a G20 engagement group.An ardent supporter of philanthropic and diversity initiatives, Geoff serves on the board of directors for the Medtronic Foundation, Children’s HeartLink, and the Northside Achievement Zone. He is part of OneTen, a coalition of cross-industry leaders committed to breaking down systemic barriers for Black Americans. He also serves as Medtronic’s Executive Sponsor to FIRST Robotics.Geoff received a bachelor’s degree in Finance from Pennsylvania State University, where he currently serves on the Development Council for its College of Liberal Arts. He was also captain of the Penn State men’s hockey team and later inducted into its Hockey Hall of Fame.